Bioventus
Bioventus' revenue fell 0.9% to $568 million in fiscal 2025. Its operating margin was 9.5%, up from −2.6% a year earlier. Free cash flow was $72 million, up 90.8%. The diluted share count rose 6.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Bioventus does
Bioventus is a medical device company focused on relieving pain and treating musculoskeletal problems, which affect bones, joints and muscles. Its products fall into three businesses: pain treatments, surgical solutions and restorative therapies.
Pain treatments include hyaluronic acid injections for knee osteoarthritis and a platelet-rich plasma system, as well as nerve stimulation products it is developing. Surgical solutions include ultrasonic tools that precisely cut bone in spine, brain and other surgery, and bone graft substitutes that help bones fuse after surgery. Restorative therapies include a low-intensity pulse ultrasound device for fractures that do not heal in the usual way. It says its injections, bone graft and fracture products account for most of its sales.
It has two reporting segments, U.S. and International, which made up 88% and 12% of its net sales in 2025.
Its biggest risks, as it describes them
- It depends on a limited number of products for its revenue and profits.
- It may be unable to develop, acquire or sell new products and expanded uses.
- It might need extra capital to fund its operations and growth.
- Weak financial controls could lead to errors in its reports.
- It faces legal proceedings, including a shareholder derivative lawsuit.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 44 | 30 | 37 | 42 | 51 |
| Debt incl. finance leases | 358 | 418 | 406 | 346 | 304 |
| Net debt (negative means net cash) | 314 | 388 | 369 | 304 | 252 |
| Net debt to EBITDA | 6.7x | — | — | 8.9x | 2.5x |
| Debt to equity | 0.8x | 1.3x | 2.3x | 2.3x | 1.6x |
| Interest coverage | 2.1x | −9.3x | −2.5x | −0.4x | 2.0x |
| Current ratio | 1.4x | 0.9x | 1.5x | 1.3x | 1.7x |
| Quick ratio | 1.1x | 0.6x | 1.0x | 0.9x | 1.2x |
Cash flow
Projections
Project Bioventus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Bioventus says to expect
- Full year 2026: adjusted earnings per share
Reaffirming its Adjusted EPS* guidance of $0.75 to $0.79 per diluted share.
- Full year 2026: net sales
Updating Net Sales guidance to $590 million to $595 million, reflecting growth of approximately 4% to 5%.
Insider trades
No officer, director or 10% owner of Bioventus reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 5 of 9 | 8 of 9 |
| Rule of 40 | 1.6% | 18.5% | 11.8% |
| Altman Z'' | −0.83 | −0.79 | 0.54 |
| Accruals ratio | −15.7% | −9.7% | −7.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 4 of 9 | 5 of 9 | 8 of 9 |
Compare
Put Bioventus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Bioventus | FY25 | −0.9% | 9.5% | 12.7% | 11.1% | 2.5x | 8 | |
| UFP Technologies | FY25 | 19.5% | 15.3% | — | 14.4% | 1.0x | 5 | Compare |
| AtriCure | FY25 | 14.9% | −1.8% | 9.0% | −1.9% | −8.9x | 7 | Compare |
| TransMedics Group | FY25 | 37.1% | 17.9% | 22.1% | 27.5% | −0.2x | 7 | Compare |
| Glaukos | FY25 | 32.3% | −39.3% | −4.4% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 340 | 321 | 431 | 512 | 512 | 573 | 568 |
| Revenue growth | — | −5.6% | 34.2% | 18.9% | 0.0% | 11.9% | −0.9% |
| Gross profit | 249 | 234 | 303 | 331 | 328 | 388 | 388 |
| Research and development | 11 | 11 | 19 | 24 | 13 | 14 | 12 |
| Operating income | 31 | 21 | 12 | −167 | −82 | −15 | 54 |
| Net income | 7 | 16 | 19 | −159 | −156 | −36 | 23 |
| Diluted EPS (US$) | — | — | −0.15 | −2.59 | −2.49 | −0.56 | 0.33 |
| Diluted shares (millions) | — | — | 46 | 61 | 63 | 64 | 69 |
| Cash flow | |||||||
| Cash from operations | 41 | 72 | 23 | −14 | 15 | 39 | 75 |
| Capital expenditure | 2 | 17 | 14 | 2 | 7 | 1 | 3 |
| Free cash flow | 38 | 55 | 9 | −15 | 8 | 38 | 72 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 263 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 20 | 18 | 3 | 13 | 13 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 64 | 87 | 44 | 30 | 37 | 42 | 51 |
| Debt incl. finance leases | — | 188 | 358 | 418 | 406 | 346 | 304 |
| Total assets | — | 494 | 1,226 | 1,373 | 811 | 728 | 684 |
| Total liabilities | — | 350 | 618 | 960 | 590 | 542 | 455 |
| Shareholders' equity | — | — | 459 | 325 | 174 | 148 | 184 |
| Margins and ratios | |||||||
| Gross margin | 73.3% | 72.7% | 70.2% | 64.7% | 64.1% | 67.7% | 68.3% |
| Operating margin | 9.2% | 6.6% | 2.8% | −32.7% | −15.9% | −2.6% | 9.5% |
| Net margin | 2.0% | 5.1% | 4.5% | −31.0% | −30.5% | −6.3% | 4.0% |
| Free cash flow margin | 11.3% | 17.2% | 2.2% | −2.9% | 1.6% | 6.6% | 12.7% |
| Rule of 40 (growth + FCF margin) | — | 11.6% | 36.4% | 15.9% | 1.6% | 18.5% | 11.8% |
| Return on capital | — | — | — | −15.3% | −9.3% | −2.2% | 11.1% |
| Return on equity | — | — | — | −40.5% | −62.6% | −22.5% | 13.7% |
| Return on assets | — | — | 2.2% | −12.2% | −14.3% | −4.7% | 3.2% |
| Net debt to EBITDA | — | 2.0x | 6.7x | — | — | 8.9x | 2.5x |